Skip to main content
SpringerLink
Log in

Störungen des Glukose-Stoffwechsels und Gewichtsveränderungen

  • Chapter
Kasuistische Beiträge zur modernen Pharmakotherapie mit Quetiapin

  • 93 Accesses

Zusammenfassung

Das Spektrum der Glukose-Stoffwechselstörungen durch Neuroleptika reicht von Störungen des Glukose-Toleranztests mit Hyperglykämie über pharmakogen induzierten Diabetes mellitus Typ II bis hin zu ketoazidotischen Zuständen. Keineswegs werden diese Stoffwechselstörungen nur durch atypische Neuroleptika ausgelöst. Zwar werden die meisten Fälle für Clozapin, gefolgt von Olanzapin, berichtet, aber auch unter Phenothiazinen und Lithium sind solche Fälle bekannt geworden (Naber et al., 2000). Wie Henderson (2002) anmerkt, wirken die Berichte über Glukose-Stoffwechselstörungen auf erfahrenere Psychiater wie Déjàvu-Erlebnisse, stand doch die Diskussion solcher Effekte bereits bei der Einführung der Phenothiazine vor mehr als 50 Jahren im Mittelpunkt des Interesses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999a; 156: 1686–1696.

    Google Scholar 

  • Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin L. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999b; 60: 215–220.

    Article  Google Scholar 

  • Allison DB, Casey DE. Antipsychotic-induced weight gain: A review of the literature. J Clin Psychiatry 2001; 62 (suppl 7): 22–31.

    Google Scholar 

  • Aquila R. Management of weight gain in patients with schizophrenia. J Clin Psychiatry 2002; 63 (suppl 4): 33–36.

    Google Scholar 

  • Branchey MH, Lee JH, Amin R, Simpson GM. High- and low- potency neuroleptics in elderly psychiatric patients. JAMA 1978; 239: 1860–1862.

    Article  Google Scholar 

  • Brecher M, Rak IW, Westhead EK, Melvin K, Jones AM. The long-term effect of quetiapine (v Seroquer) monotherapy on weight in patients with schizophrenia. Int J Clin Pract 2000; 4: 287–292.

    Article  Google Scholar 

  • Conley RR, Mahmoud R. A randomised double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158: 765–774.

    Article  Google Scholar 

  • Cookson JC. Side effects during long-term treatment with depot antipsychotic medication. Clin Neuropharmacol 1991; 14 (suppl 2): 24–30.

    Google Scholar 

  • Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Luckstedt A, Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903–912.

    Google Scholar 

  • Ganguli R, Brar JS, Ayrton Z. Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and ris¬peridone. Schizophr Res 2001; 49: 261–267.

    Article  Google Scholar 

  • Gianfrancesco FD, Grogg AL, Mahmoud RA, Eang R, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database. J Clin Psychiatry 2002; 63: 920–930.

    Article  Google Scholar 

  • Glick ID, Romano SJ, Simpson G, Home RL, Weiden P, Pigott T, Bari M. Insulin resistance in olanzapine- and ziprasidone- treated patients: Results of a double-blind, controlled 6 week trial. 154th Meeting of the APA, New Orleans 2001.

    Google Scholar 

  • Goodpaster BH, Kelley DE, Wing RR, Meier A, Theate FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999; 48: 839–847.

    Article  Google Scholar 

  • Grevich S, Melamed L, Richards R, McBurney C, Ray C, Skotschar M. Comparative side effects of atypical antipsychotics in children and adolescents. 7th World Congress of Biological Psychiatry, Berlin 2001.

    Google Scholar 

  • Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bi¬polar disorder. J Clin Psychiatry 2000; 61: 638–642.

    Article  Google Scholar 

  • Henderson DC. Atypical antipsychotic-induced diabetes mellitus. How strong is the evidence ? CNS Drugs 2002; 16: 77–89.

    Article  Google Scholar 

  • Kinon B J, Basson BR, Gilmore JA, Tollefson GD. Effect of long- term olanzapine treatment on weight change in schizophrenia. Tenth Biennial Winter Workshop on Schizophrenia, Davos, Switzerland 2000.

    Google Scholar 

  • Koren W, Kreis Y, Duchowiczny K, Prince T, Sancovici S, Sidi Y, Gur H. Lactic acidosis and fatal myocardial failure due to clozapine. Ann Pharmacother 1997; 31: 168–170.

    Google Scholar 

  • Martin A. Acute pancreatitis associated with clozapine use. Am J Psychiatry 1992; 149: 714.

    Google Scholar 

  • McIntyre RS, Mancini DA, Basile VS. Mechanism of antipsychotic-induced weight-gain. J Clin Psychiatry 2001; 62 (suppl 23): 23–29.

    Google Scholar 

  • Meyer JM. A retrospective comparison of lipid, glucose, and Glukose-Stoffwechsel weight changes at one year between olanzapine- and risperidone-treated inpatients. 41st Meeting of the New Clinical Drug Evaluation Unit, Phoenix, Arizona 2001.

    Google Scholar 

  • Naber D, Lambert M, Krausz M, Haasen C. Atypische Neuroleptika in der Behandlung schizophrener Patienten. Unimed: Bremen 2000.

    Google Scholar 

  • Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke EG. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337–345.

    Article  Google Scholar 

  • Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizmam A. Attenuation of olanzapine-induced weight-gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 297–302.

    Article  Google Scholar 

  • Sacchetti E, Guaneri L, Bravi D. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000; 48: 167–168.

    Article  Google Scholar 

  • Sernyak ML, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561–566.

    Article  Google Scholar 

  • Simpson G, Romano SJ, Horne RL, Weiden P, Pigott T, Bari M. Ziprasidone vs. olanzapine in schizophrenia: results of a double-blind trial. 41st Meeting of the New Clinical Drug Evaluation Unit, Phoenix, Arizona 2001.

    Google Scholar 

  • Tecott LH, Sun LM, Akana SF, Lowenstein DH, Dallman MF, Julius D. Eating disorder and epilepsy in mice lacking 5- HT2c serotonergic receptors. Nature 1995; 374: 542–546.

    Article  Google Scholar 

  • Wirshing DA, Spellberg BJ, Erhardt SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset of diabetes. Biol Psychiatry 1998; 44: 778–783.

    Article  Google Scholar 

  • Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358–363.

    Article  Google Scholar 

Download references

Authors
  1. Hans-Peter Volz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Krankenhauses für Psychiatrie und Psychotherapie, Schloss Werneck, Balthasar-Neumann-Platz 1, 97440, Werneck, Deutschland

    Hans-Peter Volz (Chefarzt) (Chefarzt)

  2. Klinischen Abt. für Allgemeine Psychiatrie, Universitätsklinik für Psychiatrie Wien, Währinger Gürtel 18-20, A-1090, Wien, Austria

    Siegfried Kasper (Leiter) (Leiter)

  3. Psychiatrische Universitätsklinik Klinik und Poliklinik für Psychiatrie und Psychotherapie, LMU, Nussbaumstraße 7, 80336, München, Deutschland

    Hans-Jürgen Möller (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 DUV/GWV Fachverlage GmbH, Wiesbaden

About this chapter

Cite this chapter

Volz, HP. (2004). Störungen des Glukose-Stoffwechsels und Gewichtsveränderungen. In: Volz, HP., Kasper, S., Möller, HJ. (eds) Kasuistische Beiträge zur modernen Pharmakotherapie mit Quetiapin. Deutscher Universitätsverlag. https://doi.org/10.1007/978-3-322-83447-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-322-83447-8_3

  • Publisher Name: Deutscher Universitätsverlag

  • Print ISBN: 978-3-8244-2174-9

  • Online ISBN: 978-3-322-83447-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation